FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2404605321> ?p ?o ?g. }

• W2404605321 endingPage "C103" @default.
• W2404605321 startingPage "C103" @default.
• W2404605321 abstract "Abstract Understanding the in vivo responses to immunoregulatory agents provides a basis for building more efficacious combination regimens. Pharmacologic inhibition of the oncogenic PI3Kδ pathway has been shown to be active in patients with hematopoietic malignancies. Recently, genetic inactivation of PI3Kδ in mice was shown to delay the growth of solid tumors, through the inactivation of Treg-mediated suppression of cytotoxic CD8+ T cell responses, suggesting that it may have additional utility in this patient population. We identified a similar immunomodulatory role for the PI3Kδ-selective inhibitor INCB050465 in a preclinical model of pancreatic cancer, where an increase in the number of CD8+ T cells, a decrease in the number of suppressor cells and efficacy were seen. Therefore we explored the potential of INCB050465 in additional preclinical solid tumor models, alone and in combination with other immunotherapeutic agents. INCB050465 inhibited tumor growth in multiple established tumor models which are not dependent upon oncogenic PI3K signaling. Tumor growth inhibition was not observed in these models in immunocompromised mice, demonstrating that the anti-tumor effects of these agents require an intact immune system. To further investigate immune-mediated mechanisms, tumors were analyzed for modulation of gene expression and immune phenotype after mice received short-term treatment. INCB050465 was shown to significantly downregulate the T cell gene signature in tumors, and this was primarily due to depletion of CD4+CD25+FoxP3+ regulatory T cells. As seen previously, the number of CD8+ T cells was shown to be higher in INCB050465-treated tumors. The combination of PI3Kδ and JAK inhibition resulted in enhanced activity in a T-cell-inflamed model by reducing both Treg and M2 macrophages, which promotes re-activation of both CD4+ and CD8+ T cells. In addition, PI3Kδ inhibition and PD-L1 blockade resulted in enhanced efficacy by depleting Treg and prolonging T cell response over time. In summary, pharmacological inhibition of PI3Kδ can enhance anti-tumor immunity by depleting Treg while increasing the numbers of cytotoxic CD8+ T cells. These data support clinical evaluation of the mechanism, and further studies to understand the molecular basis of efficacy and complex cellular responses may provide rationale to identify individuals who may benefit from PI3Kδ inhibitor-based immunotherapy combinations in the clinic. Citation Format: Holly K. Koblish, Liang-Chuan Wang, Michael Hansbury, Yue Zhang, Gengjie Yang, Timothy Burn, Paul Waeltz, Mark Rupar, Eddy Yue, Brent Douty, Thomas Maduskuie, Nikoo Falahatpisheh, Yun-long Li, Andrew Combs, Gregory Hollis, Reid Huber, Peggy Scherle. The combination of PI3kδ-selective inhibition and immunomodulation shows efficacy in solid tumor models. [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2015 Nov 5-9; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr C103." @default.
• W2404605321 created "2016-06-24" @default.
• W2404605321 creator A5000563949 @default.
• W2404605321 creator A5005967398 @default.
• W2404605321 creator A5005999476 @default.
• W2404605321 creator A5010776860 @default.
• W2404605321 creator A5018193992 @default.
• W2404605321 creator A5018886805 @default.
• W2404605321 creator A5022438790 @default.
• W2404605321 creator A5022878448 @default.
• W2404605321 creator A5023090545 @default.
• W2404605321 creator A5027467988 @default.
• W2404605321 creator A5041340848 @default.
• W2404605321 creator A5052738583 @default.
• W2404605321 creator A5069913182 @default.
• W2404605321 creator A5074781214 @default.
• W2404605321 creator A5076394182 @default.
• W2404605321 creator A5078326497 @default.
• W2404605321 creator A5080791603 @default.
• W2404605321 date "2015-12-01" @default.
• W2404605321 modified "2023-10-16" @default.
• W2404605321 title "Abstract C103: The combination of PI3kδ-selective inhibition and immunomodulation shows efficacy in solid tumor models" @default.
• W2404605321 doi "https://doi.org/10.1158/1535-7163.targ-15-c103" @default.
• W2404605321 hasPublicationYear "2015" @default.
• W2404605321 type Work @default.
• W2404605321 sameAs 2404605321 @default.
• W2404605321 citedByCount "3" @default.
• W2404605321 countsByYear W24046053212018 @default.
• W2404605321 countsByYear W24046053212019 @default.
• W2404605321 countsByYear W24046053212020 @default.
• W2404605321 crossrefType "journal-article" @default.
• W2404605321 hasAuthorship W2404605321A5000563949 @default.
• W2404605321 hasAuthorship W2404605321A5005967398 @default.
• W2404605321 hasAuthorship W2404605321A5005999476 @default.
• W2404605321 hasAuthorship W2404605321A5010776860 @default.
• W2404605321 hasAuthorship W2404605321A5018193992 @default.
• W2404605321 hasAuthorship W2404605321A5018886805 @default.
• W2404605321 hasAuthorship W2404605321A5022438790 @default.
• W2404605321 hasAuthorship W2404605321A5022878448 @default.
• W2404605321 hasAuthorship W2404605321A5023090545 @default.
• W2404605321 hasAuthorship W2404605321A5027467988 @default.
• W2404605321 hasAuthorship W2404605321A5041340848 @default.
• W2404605321 hasAuthorship W2404605321A5052738583 @default.
• W2404605321 hasAuthorship W2404605321A5069913182 @default.
• W2404605321 hasAuthorship W2404605321A5074781214 @default.
• W2404605321 hasAuthorship W2404605321A5076394182 @default.
• W2404605321 hasAuthorship W2404605321A5078326497 @default.
• W2404605321 hasAuthorship W2404605321A5080791603 @default.
• W2404605321 hasConcept C150903083 @default.
• W2404605321 hasConcept C154317977 @default.
• W2404605321 hasConcept C167672396 @default.
• W2404605321 hasConcept C202751555 @default.
• W2404605321 hasConcept C203014093 @default.
• W2404605321 hasConcept C207001950 @default.
• W2404605321 hasConcept C2776090121 @default.
• W2404605321 hasConcept C2779727006 @default.
• W2404605321 hasConcept C2908647359 @default.
• W2404605321 hasConcept C502942594 @default.
• W2404605321 hasConcept C55493867 @default.
• W2404605321 hasConcept C62478195 @default.
• W2404605321 hasConcept C71924100 @default.
• W2404605321 hasConcept C79484868 @default.
• W2404605321 hasConcept C86554907 @default.
• W2404605321 hasConcept C86803240 @default.
• W2404605321 hasConcept C8891405 @default.
• W2404605321 hasConcept C95444343 @default.
• W2404605321 hasConcept C99454951 @default.
• W2404605321 hasConceptScore W2404605321C150903083 @default.
• W2404605321 hasConceptScore W2404605321C154317977 @default.
• W2404605321 hasConceptScore W2404605321C167672396 @default.
• W2404605321 hasConceptScore W2404605321C202751555 @default.
• W2404605321 hasConceptScore W2404605321C203014093 @default.
• W2404605321 hasConceptScore W2404605321C207001950 @default.
• W2404605321 hasConceptScore W2404605321C2776090121 @default.
• W2404605321 hasConceptScore W2404605321C2779727006 @default.
• W2404605321 hasConceptScore W2404605321C2908647359 @default.
• W2404605321 hasConceptScore W2404605321C502942594 @default.
• W2404605321 hasConceptScore W2404605321C55493867 @default.
• W2404605321 hasConceptScore W2404605321C62478195 @default.
• W2404605321 hasConceptScore W2404605321C71924100 @default.
• W2404605321 hasConceptScore W2404605321C79484868 @default.
• W2404605321 hasConceptScore W2404605321C86554907 @default.
• W2404605321 hasConceptScore W2404605321C86803240 @default.
• W2404605321 hasConceptScore W2404605321C8891405 @default.
• W2404605321 hasConceptScore W2404605321C95444343 @default.
• W2404605321 hasConceptScore W2404605321C99454951 @default.
• W2404605321 hasIssue "12_Supplement_2" @default.
• W2404605321 hasLocation W24046053211 @default.
• W2404605321 hasOpenAccess W2404605321 @default.
• W2404605321 hasPrimaryLocation W24046053211 @default.
• W2404605321 hasRelatedWork W130785812 @default.
• W2404605321 hasRelatedWork W1557803273 @default.
• W2404605321 hasRelatedWork W1754949563 @default.
• W2404605321 hasRelatedWork W1992037894 @default.
• W2404605321 hasRelatedWork W2020684972 @default.
• W2404605321 hasRelatedWork W2059748759 @default.
• W2404605321 hasRelatedWork W2066417578 @default.
• W2404605321 hasRelatedWork W2605781369 @default.

• next